Clinical Retrospective Evidence

Clinical Retrospective Evidence

In a Phase II study, Personalized TumorGraft™ data predicted patient outcomes1:

  • Phase II study in patients with pancreatic ductal adenocarcinoma.
  • 26 patients were clinically treated with gemcitabine following pancreatectomy and tumor resection.
  • 26 TumorGrafts treated with gemcitabine and assessed for responsiveness
  • The response rate to gemcitabine in the TGs (13%) was similar to that reported in the clinic. (LINK to this graph on it’s own page and add the key from the notes below))
    chart-thumb-predictive-value-01chart-thumb-predictive-value-02
  • There was a trend for longer DFS in patients predicted sensitive by the TumorGraft model.
  • Disease-free survival was nearly four-fold in patients predicted to be sensitive to gemcitabine therapy per TumorGraft data vs. TumorGraft non-responders (>800 vs. 206 days, P=0.08)
Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology